Salarius Pharmaceuticals is an oncology-based biotechnology company developing new therapies to address gene dysregulation.
Salarius Pharmaceuticals has raised $7.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in November 2025.
Salarius Pharmaceuticals's investors include Cancer Prevention and Research Institute of Texas, Keiretsu Capital, TCA Venture Group.
Salarius Pharmaceuticals is headquartered in Houston, United States.
Salarius Pharmaceuticals is an oncology-based biotechnology company developing new therapies to address gene dysregulation.
Salarius Pharmaceuticals is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Salarius Pharmaceuticals — Funding & Investors." VCBacked, November 11, 2025, https://www.vcbacked.co/company/salarius-pharmaceuticals. Accessed August 15, 2026.
VCBacked. (2025). Salarius Pharmaceuticals — Funding & Investors. Retrieved August 15, 2026, from https://www.vcbacked.co/company/salarius-pharmaceuticals
{{cite web |title=Salarius Pharmaceuticals — Funding & Investors |url=https://www.vcbacked.co/company/salarius-pharmaceuticals |website=VCBacked |access-date=August 15, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated